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Background: KG-135, a standardized formulation enriched with Rk1, Rg3, and Rg5 ginsenosides, has been
shown to inhibit various types of cancer cells; however, the underlying mechanisms are not fully un-
derstood. In this study, we explored its effects in A549 human lung cancer cells to investigate the in-
duction of Forkhead Class box O3a (FOXO3a) and autophagy.
Methods: Cell viability was determined by sulforhodamine B staining. Apoptosis and cell cycle distri-
bution were analyzed using ﬂow cytometry. The changes of protein levels were determined using
Western blot analysis. Autophagy induction was monitored by the formation of acidic vesicular organ-
elles stained with acridine orange.
Results: KG-135 effectively arrested the cells in G1 phase with limited apoptosis. Accordingly, a decrease
of cyclin-dependent kinase-4, cyclin-dependent kinase-6, cyclin D1, and phospho-retinoblastoma pro-
tein, and an increase of p27 and p18 proteins were observed. Intriguingly, KG-135 increased the tumor
suppressor FOXO3a and induced the accumulation of autophagy hallmark LC3-II and acidic vesicular
organelles without an increase of the upstream marker Beclin-1. Unconventionally, the autophagy
adaptor protein p62 (sequestosome 1) was increased rather than decreased. Blockade of autophagy by
hydroxychloroquine dramatically potentiated KG-135-induced FOXO3a and its downstream (FasL) ligand
accompanied by the cleavage of caspase-8. Meanwhile, the decrease of Bcl-2 and survivin, as well as the
cleavage of caspase-9, were also drastically enhanced, resulting in massive apoptosis.
Conclusion: Besides arresting the cells in G1 phase, KG-135 increased FOXO3a and induced an uncon-
ventional autophagy in A549 cells. Both the KG-135-activated extrinsic FOXO3a/FasL/caspase-8 and
intrinsic caspase-9 apoptotic pathways were potentiated by blockade of autophagy. Combination of KG-
135 and autophagy inhibitor may be a novel strategy as an integrative treatment for cancers.
Copyright 2016, The Korean Society of Ginseng, Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Panax ginsengMeyer, an important and popular medicinal plant,
has been widely used for several thousand years as a tonic, pro-
phylactic, and restorative agent in Asian countries [1]. Its remedialdicine, School of Medicine, Colleg
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pharmacological studies [2]. Recently, the anticancer functions of
P. ginseng have been increasingly recognized [3]. P. ginseng can be
classiﬁed as white or red ginseng, according to processing condi-
tions. The white ginseng is processed by air drying and the rede of Medicine, Taipei Medical University, Number 111, Section 3, Hsing-Long Road,
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the pharmacological activities [4]. Several speciﬁc ginsenosides are
contained in red ginseng but not detected in white ginseng [5].
These red ginseng-speciﬁc ginsenosides have been shown to exert
more potent cytostatic or cytotoxic activity than other ginsenosides
in various cancer cells [6,7]. Sun ginseng, a speciﬁc heat-processed
ginseng, was developed in order to increase the content of Rk1, Rg3,
and Rg5 ginsenosides, which have not been isolated from white
ginseng and thus exhibit more anticancer activities [8]. Recently,
increasing the content of ginsenosides Rk1, Rg3, and Rg5 by
microwave-assisted processing was shown to enhance the anti-
cancer effects of P. ginseng extract [9], inicating the crucial roles of
these three ginsenosides in the anticancer activities of P. ginseng.
The anticancer ginsenosides of sun ginseng are present in a
butanol-soluble fraction, known as KG-135 [8], that contains equal
amounts of Rk1, Rg3, and Rg5 [5]. This standardized ginsenoside-
rich fraction, KG-135, has been shown to inhibit 12-O-tetradeca-
noylphorbol-13-acetate-induced cyclooxygenase-2 expression in
human breast epithelial cells by blocking the c-Jun N-terminal ki-
nase/activator protein-1 signaling pathway [10], suppressing the
proliferation of human prostate cancer cells both in vitro and in vivo
[8], downregulating G1 cyclin-dependent kinase through the
proteasome-mediated pathway [5], and potentiating etoposide-
induced apoptosis in human cervical cancer cells [11]. The anti-
cancer effects shown in previous studies of KG-135 are substantial
and effective; however, the extent of apoptosis induction by KG-135
in cancer cells seems limited. Some molecular events might serve
as prosurvival mechanisms, by which the cancer cells escape from
KG-135-induced apoptotic cell death.
Autophagy is an evolutionarily conserves the intracellular
degradation process, which sequestrates cytoplasmic components
and organelles to form a double-membraned autophagosome for
subsequent lysosomal degradation. The degradation products are
transported back to the cytoplasm for biosynthesis or energy pro-
duction [12,13]. In addition to the turnover of cellular proteins and
organelles, autophagy has been implicated in various physiological
and pathophysiological functions, including starvation adaptation,
cellular differentiation and death, antiaging, elimination of micro-
organisms, antigen presentation, cancer development, and treat-
ment response, etc., [14e16]. It is considered an adaptive response
to maintain cell survival under different stress conditions by
ensuring metabolic supply or removing protein aggregates and
abnormal organelles. However, beyond a certain threshold, exces-
sive degradation by autophagy ignites a nonapoptotic (Type II)
programmed cell death [15,17]. Increasing evidence indicates that
autophagy constitutes a potential target for cancer therapy [18].
Activation of prosurvival autophagy protects some cancer cells
against anticancer treatments by blocking the apoptotic pathway,
although some therapies could induce autophagic cell death in
cancer cells. Manipulation of autophagy has been suggested as a
potential strategy to improve anticancer therapies [18,19].
In addition to apoptosis, autophagy inductionwas also observed
in cancer cells treated with ginsenoside Rg3 [20] or microwave-
irradiated P. ginseng extract containing higher content of Rk1, Rg3,
and Rg5 [9]. How autophagy affects the anticancer activity of
ginsenoside-rich fractions such as KG-135 has not been reported. It
is tempting to investigate the related crucial molecular events.
Lung cancer is themost common cancer and the leading cause of
cancer death worldwide [21]. Nonsmall cell lung cancer (NSCLC)
constitutes more than 80% of lung cancers. Because NSCLC is rela-
tively resistant to chemotherapy and radiation therapy, the 5-yr
survival rate is poor and hardly reaches 20% [22e24]. New ap-
proaches are needed to tackle this disease. As such, natural phy-
tochemicals like ginsenosides or their derivatives have being
studied for their potential in NSCLC treatment [25e30].Please cite this article in press as: Yao C-J, et al., Induction of Forkhead Cla
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NSCLC cells and investigate the role of autophagy in KG-135-
mediated anticancer activities. In addition to the regulation of G1/S
transition machinery components, our results show KG-135 in-
creases theprotein level of tumor suppressor ForkheadClass boxO3a
(FOXO3a), which positively regulates genes that promote cell cycle
arrest and apoptosis [31]. Moreover, we found an unconventional
autophagy in KG-135-treated cells as the accumulation of LC3-II was
not onlywithout change of Beclin-1, butwas also accompanied by an
increase of p62 (sequestosome 1). Blockade of autophagy by
hydroxychloroquine (HCQ) potentially enhances the KG-135-
mediated increase of FOXO3a and its downstream death receptor
ligand Fas ligand (FasL), as well as the decrease of survivin and Bcl-2,
resulting in massive apoptosis. Autophagy appears to be a survival
factor for the cancer cells to escape the apoptotic death induced by
KG-135. Combing KG-135 with autophagy inhibitor might be a po-
tential strategy as an integrative medicine for cancer treatment.
2. Materials and methods
2.1. Cell culture
The human NSCLC A549 and normal human fetal lung ﬁbroblast
WI-38 cell lines were purchased from the American Type Culture
Collection (Manassas, VA, USA). A549 and WI-38 cells were main-
tained in Roswell Park Memorial Institute (RPMI)-1640 and Dul-
becco’s Modiﬁed Eagle Medium (Gibco, Grand Island, NY, USA),
respectively, supplemented with 10% fetal bovine serum (Caisson,
North Logan, UT, USA), 1  penicillinestreptomycineglutamine
(Corning, Manassas, VA, USA), and 1  nonessential amino acids
(Corning, Manassas, VA, USA). Cells were cultured at 37C in a
water-jacketed 5% CO2 incubator.
2.2. Reagents and chemicals
The quality-controlled standardized ginsenoside formulation
KG-135 was prepared as described previously [11] and supplied
from the Ginseng Science Inc. (Seoul, Korea). It was dissolved in
dimethylsulfoxide (Sigma, St. Louis, MO, USA) and diluted in sterile
culture medium immediately prior to use. The ﬁnal concentrations
of dimethylsulfoxide were all below 0.1%. Sulforhodamine B (SRB),
trichloroacetic acid, acridine orange, propidium iodide, HCQ, and
metformin were purchased from Sigma.
2.3. Assessment of the cell viability
A549 and WI-38 cells were seeded respectively in 96-well plate
at a density of 1,600 cells/well for 24 h and then treated with drugs
or sterile culture medium for 72 h. The cell viability was measured
with SRB binding assay. Brieﬂy, the cells were ﬁxed with 10% tri-
chloroacetic acid and incubated for 1 h at 4C. The plates were then
washed twice with tap water and air dried. The dried plates were
stainedwith 80 mL of 0.4% (w/v) SRB prepared in 1% (v/v) acetic acid
for 30 min at room temperature. The plates were rinsed quickly
twice with 1% acetic acid to remove unbound SRB, and then air
dried until no moisture was visible. The bound dye was solubilized
in 20 mmol/L Tris base (200 mL/well) for 5 min on a shaker. Optical
densities were read on a microplate reader (ELx800; BioTek,
Winooski, VT, USA) at 570 nm. The optical density is directly pro-
portional to the cell number over a wide range.
2.4. Analysis of cell-cycle distribution and sub-G1 apoptotic fraction
One day after being seeded in a six-well plate (5  104 cells/mL,
2 mL/well), the A549 cells were treated with agents as indicated inss box O3a and apoptosis by a standardized ginsenoside formulation,
r cells, Journal of Ginseng Research (2016), http://dx.doi.org/10.1016/
Fig. 1. Effects of KG-135 on the proliferation and cell cycle distribution of A549 human nonsmall cell lung cancer cells. (A) After treatment with KG-135 for 72 h, the cell viability of
A549 cells was measured using sulforhodamine B binding assay. (B) The cell cycle distribution was analyzed using ﬂow cytometry. Cell viability data are expressed as
mean  standard error and analyzed as described in Section 2.
C.-J. Yao et al / KG-135 induces FOXO3a and autophagy 3the ﬁgure legends for 72 h. At harvest, cells were ﬁxed in ice-cold
70% ethanol and stored at 20C. Cells were then washed twice
with ice-cold phosphate-buffered saline and then incubated with
RNase and DNA intercalating dye propidium iodide (50 mg/mL) at
room temperature for 20 min. The percentages of sub-G1 apoptotic
fraction and cell-cycle distributionwere then analyzed using a ﬂow
cytometer (Beckman Coulter EPICS XL, Fullerton, CA, USA).
2.5. Western blot
A549 cells were seeded in 10-cm dishes at a density of
4105 cells/dish for 24 h and then treated with agents as described
in the ﬁgure legends. On the day of harvest, the whole-cell lysates
were prepared with 1  radioimmunoprecipitation lysis buffer
(Millipore, Billerica, MA, USA) containing 1  tyrosine phosphatase
inhibitor cocktail (FC0020-0001; BIONOVAS, Toronto, Canada),
1protease inhibitor cocktail, full range (FC0070-0001, BIONOVAS),
and 1  serine/threonine phosphatase inhibitor cocktail (FC0030-
0001, BIONOVAS). The protein extracts were subjected to sodium
dodecyl sulfateepolyacrylamide gel electrophoresis and transferred
to polyvinylidene diﬂuoride membrane (GE Healthcare, Pittsburgh,
PA, USA) by electroblotting. The membranes were blocked with 5%
bovine serum albumin in Tris-buffered saline and Tween 20 (25mM
Tris-HCl, 125mM NaCl, 0.1% Tween 20) for 1 h at room temperature
and probed with primary antibody overnight at 4C and then with
horseradish peroxidaseeconjugated secondary antibody for 1 h at
roomtemperature. The immune complexeswerevisualizedusingan
enhanced chemiluminescence detection system (ECL; Perkin Elmer,
Waltham, MA, USA) according to the manufacturer’s instructions.
2.6. Antibodies
Primaryantibodies against phospho-retinoblastomaprotein (pRb)
(Ser807/811; #9308), p18 (#2896), FOXO3a (#2497), LC3-I/II (#4108),Please cite this article in press as: Yao C-J, et al., Induction of Forkhead Cla
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cleavedcaspase-9 (Asp315;#9505), andFasL (#4273)werepurchased
fromCell Signaling (Danvers,MA, USA). Primaryantibodies for cyclin-
dependent kinase (CDK)4 (ab68266), CDK6 (ab124821), cyclin D1
(ab134175), glyceraldehyde 3-phosphate dehydrogenase (ab8245),
and Bcl-2 (ab32124) were purchased from Abcam (Cambridge, MA,
USA). Primary antibody for Rb (sc-102) was purchased from Santa
Cruz Biotechnology (San Diego, CA, USA). Primary antibodies for p27
(1591-1), Beclin-1 (2026-1), and full-length caspase-8 (1006-1) were
purchased from Epitomics (Burlingame, CA, USA).
2.7. Detection of acidic vesicular organelles
Autophagy is featured by the formation of autophagosomes and
autolysosomes, which are acidic vesicular organelles (AVOs) [32].
Acridine orange, a weak base dye, moves freely across biological
membranes and emits green ﬂuorescence when uncharged. Its
protonated form accumulates in AVOs (consisting predominantly of
autophagosomes and autolysosomes), where it forms aggregates
that emit red ﬂuorescence [32,33]. To analyze the formation of
AVOs, the A549 cells were seeded in a six-well plate and treated as
described in the ﬁgure legends. After 72 h of treatment, the cells
were stained with acridine orange (5 mg/mL) for 20 min at room
temperature. After washing out the excess dye, green (510e
530 nm) and red (>650 nm) ﬂuorescence emission from cells
illuminated with blue (488 nm) excitation light was visually
examined under a ﬂuorescence microscope (ECLIPSE TE300; Nikon,
Tokyo, Japan) and quantiﬁed using ﬂow cytometry (EPICS XL;
Beckman Coulter, Fullerton, CA, USA), respectively.
2.8. Photograph of the cells
The phase contrast images of cells were photographed using a
digital microscope camera (PAXcam2þ,Villa Park, IL, USA) adaptedss box O3a and apoptosis by a standardized ginsenoside formulation,
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Fig. 2. Effects of KG-135 and autophagy inhibitor hydroxychloroquine (HCQ) on the cell viability of normal human fetal lung ﬁbroblast WI-38 cells. (A) After treatment with KG-135
alone or in the presence of HCQ for 72 h, the cell viability was determined using sulforhodamine B binding assay and (B) examined using phase contrast microscopy, scale
bar ¼ 100 mm. Cell viability data are expressed as mean  standard error and analyzed as described in Section 2.
J Ginseng Res 2016;-:1e104to an inverted microscope (CKX31; Olympus, Tokyo, Japan) at 10
objective lens magniﬁcation. The images of acridine orange-stained
AVOs were taken using a digital microscope camera (SPOT FLEX;
Diagnostic Instruments, Sterling Heights, MI, USA) under a ﬂuo-
rescence microscope (ECLIPSE TE300; Nikon, Tokyo, Japan) at 20
objective lens magniﬁcation.2.9. Statistical analysis
Cell viability data are expressed as mean  standard error. In
Figs. 1A, 2A, differences between groups were evaluated using one-
way analysis of variance followed by Dunnett’s t-test. SigniﬁcancePlease cite this article in press as: Yao C-J, et al., Induction of Forkhead Cla
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j.jgr.2016.04.003values are represented by single (p < 0.05), double (p < 0.01), and
triple (p < 0.001) asterisks.3. Results
3.1. KG-135 arrests the cell cycle of A549 human NSCLC cells in G1-
phase
A549 human NSCLC cells were treated with various concentra-
tions of KG-135 for 72 h and then the cell viability was measured
using SRB staining assay. As shown in Fig. 1A, KG-135 dose-
dependently inhibited the proliferation of A549 cells, with IC50 atss box O3a and apoptosis by a standardized ginsenoside formulation,
r cells, Journal of Ginseng Research (2016), http://dx.doi.org/10.1016/
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135was due to apoptosis induction or cell-cycle regulation, analysis
of cellular DNA content was performed using ﬂow cytometry after
staining the cells with propidium iodide. After 72 h of treatment,
the percentage of cells in G1 phase was markedly increased from
66.5% of control to 83.6% of 100 mg/mL KG-135-treated cells
(Fig. 1B). Reciprocally, the percentages of cells in S and G2/M phases
were decreased from 14% and 19.5% to 6.9% and 9.6%, respectively.
Nevertheless, the sub-G1 apoptotic fractionwasminimally elevated
from 1.8% to 6.3% (Fig. 1B). Apparently, at doses <100 mg/mL, the
effect of KG-135 against A549 cells is mainly attributed to G1 phase
arrest rather than apoptosis induction.
3.2. KG-135 regulates the protein levels of G1/S transition
components and tumor suppressor FOXO3a in A549 human NSCLC
cells
We then analyzed the cell cycle regulatory proteins controlling
the G1-S phase transition in cells treated with KG-135. The results
show that KG-135 markedly decreased the protein levels of CDK4,
CDK6, and cyclin D1 (Fig. 3A). As these CDKs and cyclin proteins
could inactivate Rb by phosphorylation, the phosphorylation of Rb
was dose-dependently inhibited accordingly (Fig. 3A). In addition,
the cyclin-dependent kinase inhibitors able to arrest the cell cycle
in G1 phase, such as p18 and p27, were upregulated (Fig. 3B). As p27
is a downstream target of tumor suppressor FOXO3a [34], we
examined the effect of KG-135 on this tumor suppressor in A549
cells. Intriguingly, we found the protein level of FOXO3a was
actually increased after treatment with KG-135 (Fig. 3C).
3.3. KG-135 induces autophagy in A549 human NSCLC cells without
signiﬁcant increase of Beclin-1
In spite of the substantial effects of KG-135 against the prolif-
eration of A549 cells shown in Figs. 1, 3, the extent of apoptosis was
very limited. As autophagy had been shown to protect some cancer
cells against drug treatment-induced apoptotic cell death [19], we
analyzed the autophagy markers in KG-135-treated A549 cells. As
shown in Fig. 4A, treatment of A549 cells with KG-135 dose-
dependently increased the protein of LC3-II, a hallmark of auto-
phagy. Unlike canonical autophagy, the upstream autophagyFig. 3. Effects of KG-135 on the cell cycle regulation proteins and tumor suppressor FOXO3a o
Western blot was used to analyze the protein levels of cyclin-dependent kinase (CDK)4, CDK
O3a; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; pRb, phospho-retinoblastoma p
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KG-135, indicating that such an increase of LC-3-II was Beclin-1
independent. Autophagy induction is often associated with a
decrease of the autophagy substrate and adaptor protein, p62
(sequestosome 1) [35]. However, treatment with KG-135 increased
p62 rather than decreased it (Fig. 4A). In contrast, as shown in
Fig. 4B, metformin induced LC3-II accompanied by an increase of
Beclin-1 and a decrease of p62 in A549 cells similar to its effects on
conventional autophagy induction in esophageal squamous cell
carcinoma cells [36].
We further analyzed the autophagic ﬂux in KG-135-treated
A549 cells. According to the guidelines proposed by Mizushima
and Yoshimori [37], the LC3-II accumulation by autophagy induc-
tion would be enhanced by an autophagy inhibitor like HCQ. As
shown in Fig. 5A, the increases of LC3-II induced by 50 mg/mL and
75 mg/mL of KG-135 were both substantially further enhanced by
HCQ (25mM), suggesting the induction of autophagic ﬂux.
Autophagy is featured by the formation of autophagosomes and
autolysosomes, which are AVOs [32]. As described in Section 2,
these AVOs could be stained by acridine orange and ﬂuorescence
bright red when excited at 488 nm. The results shown in Fig. 5B
show that vital staining of A549 cells with acridine orange revealed
the appearance of AVOs after treatment with KG-135 in a dose-
dependent manner. The AVOs in KG-135-treated cells showed
bright red, whereas the cytoplasm and the nucleus showed domi-
nant green ﬂuorescence. In contrast, the control cells exhibited
mainly green ﬂuorescence (Fig. 5B). Because HCQ inhibits auto-
phagy at the late stage, it could also enhance the accumulation of
AVOs induced by autophagic ﬂux [38]. In agreement with this, the
formation of AVOs induced by KG-135 (50 mg/mL) was also further
enhanced when cotreated with 25mM of HCQ (Fig. 5B). The green
and red ﬂuorescent intensities in acridine orange-stained A549
cells were quantiﬁed by ﬂow cytometric analysis. In Fig. 5C, green
(x-axis, 510e530 nm, FL1 channel) and red (y-axis, >650 nm, FL3
channel) ﬂuorescence emission with blue (488 nm) excitation
produced from stained A549 cells was measured. The percentage of
cells with bright red ﬂuorescence (the upper two FL3-positive
quadrants) is indicated in the parentheses of each dot plot. KG-
135 dose-dependently increased the percentage from 2.6% to
7.2%, 13.7%, and 30.7% at a dose of 50 mg/mL, 75 mg/mL, and 100 mg/
mL, respectively (Fig. 5C). In the presence of HCQ (25mM), the KG-f A549 human nonsmall cell lung cancer cells. (A) After treatment with KG-135 for 72 h,
6, cyclin D1, Rb, and pRb, (B) p18 and p27, and (C) FOXO3a. FOXO3a, Forkhead Class box
rotein.
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Fig. 4. Effects of KG-135 and metformin on autophagy related proteins in A549 human nonsmall cell lung cancer cells. (A) After treatment with KG-135 or (B) metformin for 72 h,
Western blot was used to analyze the protein levels of LC3-I, LC3-II, Beclin-1, and p62 (sequestosome 1). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
J Ginseng Res 2016;-:1e106135 (50 mg/mL)-induced positive acridine orange staining was
further increased to 48.1%, compared with 20.5% (HCQ) and 7.2%
(KG-135) if treated alone (Fig. 5C).
Based on these results, KG-135 induced a Beclin-1-independent
noncanonical/unconventional autophagy in A549 human NSCLC
cells.3.4. Blockade of autophagy potentiates KG-135-induced FOXO3a
and apoptosis in A549 human NSCLC cells
To investigate the role of autophagy on KG-135 mediated anti-
cancer effects, the survival of KG-135-treated A549 cells was
determined in the presence of an autophagy inhibitor HCQ. As
shown in Fig. 6A, treatment with HCQ (25mM) alone only slightly
reduced the cell viability to 83% of control. In the presence of HCQ
(25mM), the cell viability of KG-135 (75 mg/mL)-treated cells was
dramatically reduced from 64.3% to 3% of control (Fig. 6A). Com-
bination of these two agents resulted in drastic reduction of cell
viability and shrinkage of cell shape (Fig. 6B). To further examine
whether this enhancement by HCQwas due to apoptosis induction,
the sub-G1 (apoptotic) percentages were analyzed. As shown in
Fig. 6C, the sub-G1 fractions induced by HCQ (25mM) and KG-135
(75 mg/mL) alone were only 0.9% and 2.2%, respectively; however,
the sub-G1 fraction was dramatically enhanced to 60.1% when
cotreated with these two agents (Fig. 6C). Similar enhancement of
apoptosis was also observed in A549 cells treated with 50 mg/mL of
KG-135 combined with HCQ (25mM; Fig. S1). The enhancement of
HCQ on KG-135-mediated anticancer effects was mainly due to
apoptosis induction.
To evaluate the safety of KG-135 in normal lung cells, we
examined the effect of KG-135 on the cell viability of normal human
fetal lung ﬁbroblast WI-38 cells. At a dose range of 100 mg/mL, KG-
135 has no signiﬁcant suppressive effect on the viability of WI-38
cells (Fig. 2A). Combining KG-135 (75 mg/mL) with HCQ (25mM)
only slightly reduced the cell viability of WI-38 cells to 77% of
control (Fig. 2A) and most of the treated cells showed intact
morphology (Fig. 2B), in contrast to that of A549 NSCLC cells shown
in Fig. 6.
The FOXO3a protein in A549 cells decreases with the culture
time (Fig. S2). The enhancement of KG-135-induced FOXO3a by
cotreatment with HCQ (25mM) could be observed after 24 h ofPlease cite this article in press as: Yao C-J, et al., Induction of Forkhead Cla
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after 72 h of treatment, while the FOXO3a in control cells was
decreased after culture (Fig. 7A). Accordingly, the induction of the
death receptor ligand FasL, a downstream of FOXO3a, and the
decrease of full-length caspase-8 were enhanced as well when the
cells were cotreated (Fig. 7B). Next, we examined the changes of the
protein levels of Bcl-2, survivin, and caspase-9, which play impor-
tant roles in the intrinsic (mitochondrial) apoptosis pathway. The
decrease of Bcl-2 and survivin proteins by KG-135 was markedly
enhanced in the presence of HCQ (Fig. 7C). Similar enhancement
was observed in the cleavage of caspase-9. Two cleaved forms of
caspase-9 (cleavage at Asp315 and Asp330) were obviously more
elevated in the cells treated with both KG-135 and HCQ (Fig. 7C),
suggesting the contribution of an intrinsic apoptosis pathway in
this enhancement of apoptosis induction. Therefore, blockade of
autophagy in KG-135-treated A549 cells activates both the mito-
chondrial intrinsic and death receptor-mediated extrinsic apoptotic
pathways.4. Discussion
KG-135 is a quality-controlled standardized formulation
enriched with the red ginseng-speciﬁc antitumorigenic ginseno-
sides such as Rk1, Rg3, and Rg5 [11]. It had been shown to induce
marked G1 cell cycle arrest in prostate and cervical cancer cells. In
these previous studies, although a limited amount of early
apoptosis was found in KG-135-treated prostate cancer cells (PC3
and DU-145), the late stage of apoptosis (sub-G1 fraction) was
minimally elevated even at dose of 150 mg/mL [5,8]. Similarly, the
sub-G1 fraction is also minimally increased in KG-135-treated A549
human NSCLC cells even at dose of 100 mg/mL, in spite of the
marked induction of G1 cell-cycle arrest. According to recent
ﬁndings in the adaptive response of cancer cells to drug treatment
[18], it is tempting to speculate that a prosurvival autophagy was
induced by KG-135, by which the cancer cells escaped from
apoptotic death. In agreement with this speculation, our results
demonstrate the autophagy ﬂux induced by KG-135 and show that
an autophagy inhibitor like HCQ could dramatically enhance KG-
135-induced apoptosis of A549 cells.
Chloroquine (CQ) and its derivative HCQ are the only autophagy
inhibitors whose effectiveness and safety in clinical trials have beenss box O3a and apoptosis by a standardized ginsenoside formulation,
r cells, Journal of Ginseng Research (2016), http://dx.doi.org/10.1016/
Fig. 5. Effects of autophagy inhibitor hydroxychloroquine (HCQ) on KG-135-induced LC3-II accumulation and acidic vesicular organelle (AVO) formation in A549 human nonsmall
cell lung cancer cells. (A) After treatment with KG-135 alone or in the presence of HCQ for 72 h, the protein levels of LC3-I and LC3-II were analyzed byWestern blot. (B) As described
in Section 2, the formation of acridine orange-stained AVOs was examined using ﬂuorescence microscopy, scale bar ¼ 50 mm and (C) quantiﬁed using ﬂow cytometry. The AVOs in
KG-135-treated cells showed bright red, whereas the cytoplasm and the nucleus showed dominant green ﬂuorescence. The percentage of cells with bright red ﬂuorescence (the
upper two FL3-positive quadrants) is indicated in the parentheses of each ﬂow cytometric dot plot. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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Fig. 6. Effects of autophagy inhibitor hydroxychloroquine (HCQ) on KG-135-mediated
growth inhibition and apoptosis induction in A549 human nonsmall cell lung cancer
cells. (A) After treatment with KG-135 alone or in the presence of HCQ for 72 h, the cell
viability was determined using sulforhodamine B binding assay and (B) examined
using phase contrast microscopy, scale bar ¼ 100 mm. (C) The sub-G1 apoptotic fraction
was analyzed using ﬂow cytometry.
Fig. 7. Effects of autophagy inhibitor hydroxychloroquine (HCQ) on KG-135-mediated
activation of apoptosis pathways and upregulation of tumor suppressor FOXO3a in
A549 human nonsmall cell lung cancer cells. (A) The protein level of FOXO3a was
analyzed using Western blot after treatment with KG-135 alone or in the presence of
HCQ for 24 h and 72 h. (B) The extrinsic apoptosis-related proteins Fas ligand (FasL)
and full-length caspase-8 were analyzed using Western blot after treatment with KG-
135 alone or in the presence of HCQ for 48 h. (C) The mitochondrial (intrinsic)
apoptosis-related proteins were analyzed using Western blot 48 h (survivin and
caspase-9 cleaved at Asp315 and Asp330) and 72 h (Bcl-2) after treatment with KG-135
alone or in the presence of HCQ. FOXO3a, Forkhead Class box O3a; GAPDH, glyceral-
dehyde 3-phosphate dehydrogenase.
J Ginseng Res 2016;-:1e108approved by the Food and Drug Administration [18]. In comparison
with CQ, HCQ can be safely dose escalated in cancer patients
[18,39]. Thus, we chose HCQ for autophagy inhibition to potentiate
the anticancer efﬁcacy of KG-135 in this study.
The induction of p27 by KG-135 had been shown in Hela human
cervical cancer cells by Lee et al. [5]. In A549 NSCLC cells, we alsoPlease cite this article in press as: Yao C-J, et al., Induction of Forkhead Cla
KG-135, is potentiated by autophagy blockade in A549 human lung cance
j.jgr.2016.04.003observed the increase of p27 protein level by KG-135 and further
unveiled the upregulation of the upstream tumor suppressor
FOXO3a, which positively regulates genes promoting cell cycle ar-
rest and apoptosis [31]. When the KG-135-induced FOXO3a was
drastically enhanced by HCQ, the downstream death receptor FasL
was markedly elevated accompanied by a decrease of full-length
caspase-8. Yoo et al. [8], had observed the involvement of death
receptor signaling and caspase-8 as well as apoptosis inducing
factor in the early apoptosis of KG-135-treated prostate cancer cells,
although late apoptosis (sub-G1 fraction) was only minimally
elevated. It is interesting to investigate whether these apoptotic
pathways in KG-135-treated prostate cancer cells could also be
dramatically enhanced by HCQ and result in the appearance of a
massive sub-G1 fraction.ss box O3a and apoptosis by a standardized ginsenoside formulation,
r cells, Journal of Ginseng Research (2016), http://dx.doi.org/10.1016/
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accumulation of autophagy hallmark protein LC3-II without the
increase of upstream marker Beclin-1. Moreover, the autophagy
substrate and adaptor protein p62 (sequestosome 1) was increased
after KG-135 treatment rather than decreased. Because p62 is
recognized as an autophagy substrate and is often degraded in
autolysosomes, accumulation of p62 could be the result of inhibi-
tion of autophagy [35]. Therefore, the results from cells treated
with KG-135 alone seemed not be sufﬁcient to determine whether
the autophagic ﬂux was promoted or inhibited. To determine the
induction of autophagic ﬂux, Mizushima and Yoshimori [37] pro-
posed that the accumulation LC3-II by autophagy induction would
be enhanced by an autophagy inhibitor like HCQ and would not be
affected if it was caused by autophagy inhibition. According to this
guideline, we examined and found the KG-135-induced accumu-
lation of LC3-II was enhanced by HCQ in A549 cells, indicating the
induction of autophagic ﬂux by KG-135. Besides LC3-II, HCQ could
also enhance the accumulation of AVOs induced by autophagic ﬂux,
because it inhibits autophagy at the late stage [38]. In line with this,
similar enhancement of KG-135-indcued AVOs by HCQ was
observed and further suggested the presence of autophagic ﬂux
induction.
Autophagy accompanied by an increase of p62 (sequestosome 1)
and without a change of Beclin-1 had also been shown in
resveratrol-treated K562 human chronic myelogenous leukemia
cells [41,42]. In that study, suppressing the p62 expression by a
speciﬁc c-Jun N-terminal kinase inhibitor SP600125 or small
interfering RNA drastically reduced the accumulation of LC3-II. The
autophagy induced by resveratrol is p62-dependent [41,42]. How-
ever, unlike the case in resveratrol-treated chronic myelogenous
leukemia cells, the c-Jun N-terminal kinase inhibitor SP600125
suppressed the increase of p62 but did not reduce the accumulation
of LC3-II in KG-135-treated A549 cells (data not shown). As the
protein level of p62 can also be changed independent of autophagy
[37], additional functions of p62 remain to be determined with
regard to its role in KG-135-induced autophagy.
Cheong et al. [20] recently reported that Rg3, one of the active
components in KG-135, induced autophagy in HepG2 hepatoma
cells evidenced by the increase of LC-3-II. Controversially, the study
by Kim et al. [43] shows that Rg3 inhibits the autophagy of HepG2
cells as the Rg3-increased LC3-II could not be further enhanced in
the presence of CQ. The explanation for this discrepancy between
the results of these two studies remains to be elucidated. However,
in A549 cells, we did ﬁnd that KG-135-induced accumulation of
LC3-II was enhanced by HCQ. As different cancer cells were used,
one possibility is that the effects of ginsenosides on autophagic ﬂux
might be quite different depending on the cellular context. Further
investigation is needed to clarify the detailed molecular events.
Taken together, in addition to the regulation of G1/S transition
machinery, we found an increase of p27 and its upstream tumor
suppressor FOXO3a in KG-135-treated A549 human NSCLC cells.
The apoptosis induction of A549 cells by KG-135 is prevented by a
prosurvival autophagy, which might be Beclin-1-independent and
noncanonical. Blockade of autophagy by HCQ activates not only the
caspase-9 but also the FOXO3a/FasL/caspase-8 apoptotic pathways.
In another human NSCLC cell line, H460 large-cell lung cancer cells,
KG-135 also induces noncanonical/unconventional autophagy, and
combinationwith HCQ also enhances KG-135-induced FOXO3a and
apoptosis (Fig. S3). Regarding the future implementation of KG-135
as an integrative anticancer therapeutics, combination of KG-135
and an autophagy inhibitor like HCQ may be a potential novel
strategy for cancer treatment.Please cite this article in press as: Yao C-J, et al., Induction of Forkhead Cla
KG-135, is potentiated by autophagy blockade in A549 human lung cance
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